Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Oral Option for Pediatric Epilepsy

UCB news release; 2017 Nov 6

UCB recently announced that the US Food and Drug Administration (FDA) has approved a label extension for the company's anti-epileptic drug (AED) Vimpat (lacosamide) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients aged ≥4 years. UCB is headquartered in Atlanta, GA, and Brussels, Belgium.

Indications: This new approval provides clinicians with the option to prescribe Vimpat to their pediatric patients either as an oral solution or a convenient tablet, allowing for flexible administration options, an important consideration when treating children.

Dosage/administration: For pediatric patients from 4 years to <17 years, the recommended dosage is based on body weight and is administered orally twice daily. Increased dosage is based on clinical response and tolerability, and no more frequently than once per week is recommended.

Adverse reactions: Adverse reactions in pediatric patients are similar those of adult patients: diplopia, headache, dizziness, and nausea.

Citation:

UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients. [news release]. Atlanta, GA, and Brussels, Belgium: UCB. November 6, 2017. https://www.prnewswire.com/news-releases/ucbs-vimpat-lacosamide-now-approved-by-fda-to-treat-partial-onset-seizures-in-pediatric-epilepsy-patients-300549924.html. Accessed November 9, 2017.

This Week's Must Reads

Fully Automated Test Gauges Processing Speed in MS, MS Mult Scler; ePub 2018 Aug 6; Patel, Shen, et al

Inflammation and Disability in Progressive-Onset MS, JAMA Neurology; ePub 2018 Aug 6; Hughes, et al

Mental Health’s Impact on Falls in Patients with MS, Mult Scler Relat Disord; ePub 2018 Jul 26; Kalron, et al

House-Call-Based Practice Viable for Advanced MS, Int J MS Care; ePub 2018 Aug 7; Healey, Zabad, et al

Detection of Chronic Active MS Lesions on 3T MRI, AJNR Am J Neuroradiol; 2018 Jul; Absinta, et al

Must Reads in Epilepsy & Seizures

Midlife Risk Factors Linked to Late-Onset Epilepsy, JAMA Neurology; ePub 2018 Jul 23; Johnson, et al

Nearly 1 Million Adults ≥55 Years Have Epilepsy, Epilepsy Behav; ePub 2018 Aug 2; Sapkota, et al

Incidental Findings Common in Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Aug 2; Doyle, et al

With Epilepsy Surgery, Age Is but a Number, Epilepsy Behav; ePub 2018 Jul 9; O’Dwyer, et al

Neuroimaging Frequency, Yield for Seizure Disorders, Epilepsia; ePub 2018 Jul 18; Salinsky, Wong, et al